Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Henry G Bone

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Obstetrics and Gynecology|July 2, 2013
Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trialChris Recknor, Edward Czerwinski, Henry G Bone, et al.
The Journal of Clinical Endocrinology and Metabolism|May 26, 2018
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal OsteoporosisHenry G Bone, Felicia Cosman, Paul D Miller, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 27, 2010
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effectJohn A Eisman, Henry G Bone, David J Hosking, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 7, 2011
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosisMichael R McClung, Steven Boonen, Ove Törring, et al.
Journal of the Endocrine Society|April 24, 2023
Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic HypoparathyroidismNelson B Watts, John P Bilezikian, Henry G Bone, et al.
Contraception|March 18, 2008
Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral densityChristine C Johnson, Ronald T Burkman, Melanie A Gold, et al.
Annals of Internal Medicine|December 3, 2002
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trialSusan L Greenspan, Ronald D Emkey, Henry G Bone, et al.
The New England Journal of Medicine|January 3, 2014
Romosozumab in postmenopausal women with low bone mineral densityMichael R McClung, Andreas Grauer, Steven Boonen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2015
Hypocalcaemia in patients with metastatic bone disease treated with denosumabJean-Jacques Body, Henry G Bone, Richard H de Boer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 5, 2008
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trialJacques P Brown, Richard L Prince, Chad Deal, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Obstetrics and Gynecology|July 2, 2013
Denosumab compared with ibandronate in postmenopausal women previously treated with bisphosphonate therapy: a randomized open-label trialChris Recknor, Edward Czerwinski, Henry G Bone, et al.
The Journal of Clinical Endocrinology and Metabolism|May 26, 2018
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal OsteoporosisHenry G Bone, Felicia Cosman, Paul D Miller, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 27, 2010
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effectJohn A Eisman, Henry G Bone, David J Hosking, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 7, 2011
Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosisMichael R McClung, Steven Boonen, Ove Törring, et al.
Journal of the Endocrine Society|April 24, 2023
Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic HypoparathyroidismNelson B Watts, John P Bilezikian, Henry G Bone, et al.
Contraception|March 18, 2008
Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral densityChristine C Johnson, Ronald T Burkman, Melanie A Gold, et al.
Annals of Internal Medicine|December 3, 2002
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trialSusan L Greenspan, Ronald D Emkey, Henry G Bone, et al.
The New England Journal of Medicine|January 3, 2014
Romosozumab in postmenopausal women with low bone mineral densityMichael R McClung, Andreas Grauer, Steven Boonen, et al.
European Journal of Cancer (Oxford, England : 1990)|June 22, 2015
Hypocalcaemia in patients with metastatic bone disease treated with denosumabJean-Jacques Body, Henry G Bone, Richard H de Boer, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 5, 2008
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trialJacques P Brown, Richard L Prince, Chad Deal, et al.
Pageof 6